Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.39 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406759 | 0.81 | CYP1A2 (0.45) | TSHRHRH3MEP1AMEP1BPTGES | |
| SCHEMBL31721197 | 0.81 | TSHR (0.48) | ALDH1A1TSHRNOS1HTR7CHRNB2 | |
| SCHEMBL153971 | 0.81 | MEP1A (0.53) | ALDH1A1TSHRNOS1HTR7HRH3 | |
| SCHEMBL6405789 | 0.80 | TSHR (0.48) | TSHRHRH3MEP1AMEP1BPTGES | |
| SCHEMBL989636 | 0.79 | ALDH1A1 (0.67) | ALDH1A1TSHRNOS1HTR7CHRNB2 | |
| SCHEMBL910601 | 0.78 | MGLL (0.43) | ALDH1A1 | |
| SCHEMBL7423782 | 0.78 | TRPA1 (0.42) | ALDH1A1TSHRMEP1AMEP1BPTGES | |
| SCHEMBL6410635 | 0.75 | HRH3 (0.56) | ALDH1A1TSHRNOS1CHRNB2CHRNA4 | |
| SCHEMBL910177 | 0.74 | DRD2 (0.40) | PTGES | |
| SCHEMBL5158276 | 0.74 | TSHR (0.46) | TSHRHRH3MEP1AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| US-20050222098-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | disclosed |
| CN-1068333-C | Sterol derivatives used for regulation of meiosis | NOVO NORDISK AS (DK) | 2001-07-11 | — | — | CN | disclosed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998008492-A1 | TRANSDERMAL DELIVERY OF PEPTIDES | NOVO NORDISK A/S (DK) | 1998-03-05 | — | — | WO | disclosed |
| CN-1151164-A | Sterol derivatives used for regulation of meiosis | NOVO NORDISK AS (DK) | 1997-06-04 | — | — | CN | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222098-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | ALDH1A1 2659/4885TSHR 4376/4885NOS1 4284/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | ALDH1A1 2659/4885TSHR 4376/4885NOS1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.